InxMed
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
InxMed - overview
Established
2017
Location
Shanghai, Shanghai, China
Primary Industry
Biotechnology
About
Established in 2017 and based in Shanghai, China, InxMed is a biotechnology company that focuses on the R&D of oncology drug resistance and tumor metastasis fields. The company established translational medicine and clinical teams in Shanghai, Beijing, and Nanjing in China, and hubs in the United States, Canada, and Australia. Moreover, the company has established cooperation with multinational pharmaceutical companies including Roche, Boehringer Ingelheim, and MSD. The company developed a new drug for ovarian cancer, IN10018, which was approved for Investigational New Drug (IND) application in April 2020, receives US FDA Fast Track Designation for ovarian cancer in August 2021, and receives the NMPA approval for a clinical trial of solid tumor in December 2021.
In August 2025, InxMed raised Series C funding led by new investor Fosun Health Capital and participants by new investors Proxima Ventures, Kunlun Capital, Chengxiang Capital, returning investor Ennovation Ventures. The company's main business is the research, development, and production of anti-cancer drugs. The company's self-developed adhesive spot kinase (FAK) inhibitor IN10018 overcomes the drug resistance of KRAS G12C inhibitors and synergizes with KRAS G12C inhibitors in treating cancer, and can treat solid tumors, and ovarian cancers. The company also developed new drugs IN 30705 targeting cancer-associated fibroblast, and IN20130 targeting epigenetic regulators.
InxMed generates revenue via researching, development, and production of anti-cancer drugs.
Current Investors
Grand Yangtze Capital, China Growth Capital, Ennovation Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.inxmed.com
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
InxMed - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & Executive Director & General Manager | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.